Results 111 to 120 of about 45,542 (206)
Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy
Medicine Bulletin, Volume 2, Issue 1, Page 61-93, January 2026.ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley +1 more source
New molecular markers in mantle cell lymphoma : studies of cannabinoid receptors, 5-lipoxygenase and SOX11 [PDF]
, 2010 Mantle cell lymphoma (MCL) is a malignant B-cell lymphoma that accounts for 5-10% of all lymphomas and tends to occur in older adults with a higher incidence in males.
Wang, Xiao
core +1 more source
Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma
Hematology Reports, 2011 The determination of prognosis for B-Non- Hodgkin’s lymphoma (NHL) is known to be related to the multiple differences in tumor cell biology. Bcl-2 and Bcl-6 are two markers linked to germinal center B cells.
Hanan Mohamed Mahmoud +1 more
doaj +1 more source
Fluorescence-based proteasome activity profiling [PDF]
, 2012 With the proteasome emerging as a therapeutic target for cancer treatment, accurate tools for monitoring proteasome (inhibitor) activity are in demand.
Berkers, C.R. +4 more
core +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.ABSTRACT Non‐Hodgkin lymphoma (NHL) is the fifth most common malignancy and accounts for 5% of all cancers in the US, with the largest proportion being B‐cell CD20 positive NHL. Odronextamab is a CD20xCD3 IgG4 bispecific T‐cell‐engaging monoclonal antibody under development for the treatment of relapsed or refractory (R/R) B‐NHL. The objectives of this
Marçal Bravo Padros +5 more
wiley +1 more source
Adhesion molecule profiles of B-cell non-Hodgkin's lymphomas in the leukemic phase
Brazilian Journal of Medical and Biological Research, 2006 We evaluated the expression of 10 adhesion molecules on peripheral blood tumor cells of 17 patients with chronic lymphocytic leukemia, 17 with mantle-cell lymphoma, and 13 with nodal or splenic marginal B-cell lymphoma, all in the leukemic phase and ...
D.M. Matos +4 more
doaj
A rare case of breast carcinoma co-existing with axillary mantle cell lymphoma
World Journal of Surgical Oncology, 2003 Background Mantle cell lymphoma (MCL) is a rare variety of non-Hodgkin's lymphoma which originates from CD5+ B-cell population in the mantle zones of lymphoid follicles. Coexistence of such tumours in the axillary lymph nodes with invasive breast cancers
Scally John +3 more
doaj +1 more source
Telomere protein complexes and their role in lymphoid malignancies [PDF]
, 2017 Telomeres are highly regulated and dynamic complexes that protect the genomic DNA and prevent the end of linear chromosomes from being misrecognized as a broken DNA.
Dos Santos, Patricia Carolina +2 more
core
British Journal of Haematology, Volume 208, Issue 1, Page 149-158, January 2026.Summary A high unmet need for novel, safe and effective therapies exists among older patients with non‐Hodgkin lymphoma (NHL). We report safety and efficacy of mosunetuzumab in a subgroup analysis of a phase I/II study, which examined the prognostic impact of age in 218 patients with relapsed/refractory (R/R) B‐cell NHL (B‐NHL; ≥65 years, n = 102; <65 ...
Swetha Kambhampati Thiruvengadam +11 more
wiley +1 more source
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas [PDF]
, 2007 Integrative genomic and gene-expression analyses have identified amplified oncogenes in B-cell non-Hodgkin lymphoma (B-NHL), but the capability of such technologies to localize tumor suppressor genes within homozygous deletions remains unexplored.
Agirre-Ena, X. (Xabier) +20 more
core